Dr. Luke on Immunotherapy Diagnostics in Melanoma

Jason Luke, MD
Published: Thursday, Oct 20, 2016



Jason Luke, MD, assistant professor of Medicine, The University of Chicago Medicine, discusses the various methods involved in immunotherapy diagnostics in the treatment landscape of melanoma.

One such method is PD-L1 immunohistochemistry. However, Luke notes, even patients who are technically negative for PD-L1 expression have been found to benefit more from these types of drugs than other agents.

Another method involves looking at the mutational load in the cancer. Some oncologists have found that, if tumors have a very high mutational rate in the cancer, the likelihood of response is very high, explains Luke.


Jason Luke, MD, assistant professor of Medicine, The University of Chicago Medicine, discusses the various methods involved in immunotherapy diagnostics in the treatment landscape of melanoma.

One such method is PD-L1 immunohistochemistry. However, Luke notes, even patients who are technically negative for PD-L1 expression have been found to benefit more from these types of drugs than other agents.

Another method involves looking at the mutational load in the cancer. Some oncologists have found that, if tumors have a very high mutational rate in the cancer, the likelihood of response is very high, explains Luke.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Community Practice Connections™: 13th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®Apr 28, 20182.0
Publication Bottom Border
Border Publication
x